


List of abbreviations

ANA	Anastrozole
BEV	Bevacizumab
CAP	Capecitabine
del	Chromosomal deletion
DOC	Docetaxel
DOX	Doxorubicin
EPI	Epirubicin
ER	Estrogen receptor
ERI	Eribulin
EXE	Exemestane
FEC	Fluorouracil + Epirubicin + Cyclophosphamide
FUL	Fulvestrant
HER2	Human epidermal growth factor receptor 2
inv	Chromosomal inversion
LET	Letrozole
M	Distant metastasis status at diagnosis (0, negative; 1, positive)
N	Positive lymph nodes at diagnosis (0, none; 1, 1–3; 2, 4–9; 3, >9)
NHG	Nottingham histological grade
PAC	Paclitaxel
PR	Progesterone receptor
RT	Radiotherapy
t	Chromosomal translocation
T	Tumor size (1, <=2cm; 2, 2–5cm; 3, >5cm)
TAM	Tamoxifen
TRA	Trastuzumab
VIN	Vinorelbine
y/o	Year old (at diagnosis)
ZOL	Zoledronate


Patient EM1 42 y/o

T2 (33 mm), N0, M0, NHG3, ER/PR pos, HER2 neg
ctDNA–detected recurrence 7 months prior to clinical recurrence




Patient EM2 57 y/o

T2 (28 mm), N1, M0, NHG2, ER/PR pos, HER2 neg
ctDNA–detected recurrence 16 months prior to clinical recurrence




Patient EM3 78 y/o

T1 (20 mm), N2, M0, NHG3, ER/PR pos, HER2 neg
No ctDNA–detected recurrence despite clinical recurrence




Patient EM4 34 y/o

T2 (28 mm), N0, M0, NHG2, ER/PR pos, HER2 neg
ctDNA–detected recurrence 4 months after clinical recurrence




Patient EM5 61 y/o


T1 (12 mm), N0, M0, NHG1, ER/PR pos, HER2 neg
ctDNA–detected recurrence 36 months prior to clinical recurrence




Patient EM6 62 y/o diagnosed with bilateral primary breast cancer
 Left tumor: T3 (55 mm), N1, M0, NHG3, ER/PR pos, HER2 neg
 Right tumor: T2 (28 mm), N1, M0, NHG2, ER/PR pos, HER2 neg
 ctDNA-detected recurrence 37 months prior to clinical recurrence




Patient EM7 55 y/o
 T2 (22 mm), N0, M0, NHG2, ER/PR pos/neg, HER2 pos
 ctDNA-detected recurrence 6 months prior to clinical recurrence




Patient EM8 67 y/o
 T2 (22 mm), N1, M0, NHG2, ER/PR pos/neg, HER2 neg
 ctDNA-detected recurrence 2 months prior to clinical recurrence




Patient EM9 50 y/o
 T1 (18 mm), N0, M0, NHG3, ER/PR pos, HER2 neg
 ctDNA-detected recurrence 13 months prior to clinical recurrence




Patient EM10 64 y/o
 T2 (45 mm), N1, M0, NHG2, ER/PR pos/neg, HER2 (neg)
 ctDNA-detected recurrence 6 months prior to clinical recurrence




Patient EM11 59 y/o
 T1 (20 mm), N3, M0, NHG3, ER/PR pos, HER2 (neg)
 ctDNA-detected recurrence 1 month prior to clinical recurrence




Patient EM12 53 y/o
T2 (37 mm), N2, M0, NHG2, ER/PR pos, HER2 neg
ctDNA–detected recurrence 4 months prior to clinical recurrence




Patient EM13 69 y/o
T2 (25 mm), N0, M0, NHG2, ER/PR pos/neg, HER2 (neg)
ctDNA–detected recurrence 8 months prior to clinical recurrence




Patient EM14 47 y/o
T1 (19 mm), N1, M0, NHG2, ER/PR neg/pos, HER2 pos
ctDNA–detected recurrence 15 months prior to clinical recurrence




Patient DF1 58 y/o
T1 (15 mm), N0, M0, NHG3, ER/PR pos, HER2 neg
No ctDNA–detected recurrence, no clinical recurrence




Patient DF2 37 y/o
T1 (20 mm), N0, M0, NHG3, ER/PR pos, HER2 neg
No ctDNA–detected recurrence, no clinical recurrence




Patient DF3 56 y/o
T1 (19 mm), N0, M0, NHG2, ER/PR pos, HER2 (neg)
No ctDNA–detected recurrence, no clinical recurrence



Patient DF4 46 y/o
T1 (13 mm), N0, M0, NHG2, ER/PR neg, HER2 (neg)
No ctDNA–detected recurrence, no clinical recurrence



Patient DF5 54 y/o
T1 (15 mm), N0, M0, NHG3, ER/PR pos, HER2 (neg)
No ctDNA–detected recurrence, no clinical recurrence



Patient DF6 58 y/o
T1 (18 mm), N0, M0, NHG2, ER/PR pos/neg, HER2 (neg)
No ctDNA–detected recurrence, no clinical recurrence

